Analiz Rodriguez

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Associate Professor

University of Arkansas UAMS primary UA Little Rock

Also affiliated: Kanazawa University (2020); Atrium Health Wake Forest Baptist (2014–2016); City Of Hope National Medical Center (2017–2022); Los Alamos National Laboratory (2004); University of Idaho (2007); University of Arkansas Medical Center (2019–2024); Cancer Institute (WIA) (2019); Oxford University Press (United Kingdom) (2020); University Medical Center (2016); New College of Florida (2004); City of Hope (2017–2022); Winthrop Rockefeller Foundation (2019–2023); Ministry of Construction and Physical Planning (2010); Neurological Surgery (2020–2022); Arkansas Department of Health (2020); Beckman Research Institute (2022); Wake Forest University (2014–2017); University of Colorado Anschutz Medical Campus (2017); Case Western Reserve University (2007–2009); Stony Brook University (2020); University of Colorado Denver (2017); Icahn School of Medicine at Mount Sinai (2017)

Faculty Researcher

Neurosurgery, College of Medicine

26 h-index 183 pubs 7,899 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Analiz Rodriguez investigates novel therapeutic strategies for glioblastoma, a highly aggressive brain tumor. Her work includes the development and evaluation of oncolytic virotherapy, such as the DNX-2401 virus, in combination with immunotherapies like pembrolizumab for recurrent glioblastoma. Rodriguez also explores the potential of CAR-T cell therapies, examining their application in solid tumors and specifically for glioblastoma, including the development of "off-the-shelf" steroid-resistant CAR T cells targeting IL13Rα2.

Her research also encompasses the creation of advanced preclinical models to better understand tumor biology and predict treatment responses. This includes utilizing zebrafish cancer avatars to analyze tumor heterogeneity and patient outcomes, as well as developing functional precision medicine pipelines that combine comparative transcriptomics and tumor organoid modeling. She has received funding from the NIH/National Cancer Institute for the development of immunocompetent melanoma brain metastases organoids. Rodriguez is a highly cited researcher with an h-index of 26 and over 180 publications.

Metrics

h-index: 26
Publications: 183
Citations: 7,899

Selected Publications

Longitudinal multi-omics characterization of the malignant evolution in multirelapsing glioblastoma (2026)

medRxiv DOI OpenAlex
Long-read sequencing for cancer liquid biopsy: advancing precision oncology (2026)

Frontiers in Oncology DOI OpenAlex
Endoscopic transsphenoidal resection of large sellar chondrosarcoma compressing the optic nerve: illustrative case (2026)

Journal of Neurosurgery Case Lessons DOI OpenAlex
ANGI-14. GLIOBLASTOMA PROGRESSION FROM TRANSCRIPTOMIC REGULATION TO BRAIN FUNCTIONAL CONNECTIVITY (2025)

Neuro-Oncology DOI OpenAlex
RADT-51. SURGICALLY TARGETED RADIATION THERAPY (START) FOR PREVIOUSLY IRRADIATED RECURRENT BRAIN METASTASES: INITIAL REPORT FROM A MULTI-INSTITUTIONAL PROSPECTIVE STUDY (2025)

Neuro-Oncology DOI OpenAlex
Laser Interstitial Thermal Therapy for Brain Tumors: a Prospective Multicenter Analysis of 787 Patients from the LAANTERN Study (2025)

SSRN Electronic Journal DOI OpenAlex
Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025)

Current Oncology DOI OpenAlex
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial (2025)

Nature Medicine 2 citations DOI OpenAlex
Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy (2025)

JAMA Neurology 9 citations DOI OpenAlex
Navigating molecular neuropathology of CNS neoplasms for the practicing surgical pathologist (2025)

American Journal of Clinical Pathology DOI OpenAlex
Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner (2025)

Cancer Research DOI OpenAlex
SURG-54. RECURRENT BRAIN METASTASES (RBM) TREATED WITH SURGICALLY TARGETED RADIATION THERAPY (START): PRELIMINARY SAFETY EVALUATION FROM A MULTI-INSTITUTIONAL PROSPECTIVE REGISTRY (2024)

Neuro-Oncology DOI OpenAlex
Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond (2024)

Frontiers in Oncology 5 citations DOI OpenAlex
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma (2024)

Scientific Reports 8 citations DOI OpenAlex
Functional precision medicine assay for recurrent meningioma: a proof of principle. Illustrative case (2024)

Journal of Neurosurgery Case Lessons 1 citation DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $76,500 total

NIH Contact PI Mar 2024 - Feb 2026

Development of immunocompetent melanoma brain metastases organoids

National Cancer Institute $76,500 R03

Grants & Funding

As listed on this researcher's institutional profile. Federal awards with verified records are shown above.

A Phase IlI Clinical Trial Evaluating DCVax-L, Autologous Dendritis Cells Pulsed Northwest Biotherapeutics, Inc. Principal Investigator
Photobiomodulation to Ameliorate Neuronal Degeneration and Cognitive Decline after Mixed Field Irradiation - Continuation National Aeronautics & Space Administration Co-Investigator
Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
Novel Platform linking cancer-specific glycosylation with cell signaling outcomes NIH Co-Investigator